8. ハンチントン病 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(2)-epigallocatechin-3-gallate (EGCG)   
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01357681   Germany;
18F-FDG   
   Universitaire Ziekenhuizen Leuven
      2020   -   NCT04701580   Belgium;
5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium   
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   EUCTR2014-000418-75-NL   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-GB   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-DE   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-CZ   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-PT   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-IT   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
ACR16   
   A. Carlsson Research AB
      2004   -   EUCTR2004-000394-60-SE   Denmark;Sweden;
      2004   -   EUCTR2004-000394-60-DK   Denmark;Sweden;
   NEUROSEARCH SWEDEN AB
      2008   -   EUCTR2007-004988-22-IT   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
   NeuroSearch Sweden AB
      2009   -   EUCTR2007-004988-22-AT   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004988-22-PT   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004988-22-GB   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004988-22-FR   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004988-22-ES   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004988-22-DE   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004988-22-BE   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
   Teva Pharmaceutical Industries
      2008   Phase 3   NCT00665223   Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
      2008   Phase 2/Phase 3   NCT00724048   Canada;United States;
ACR16 hydrochloride, ASP2314 hydrochloride, FR310826   
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 2   EUCTR2015-000904-24-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
   Teva Branded Pharmaceutical Products R&D, Inc
      2016   Phase 2   EUCTR2015-000904-24-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-GB   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-001888-23-DK   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-PL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-NL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-IT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-AT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   -   EUCTR2013-001888-23-GB   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE   
   uniQure biopharma B.V.
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-PL   Poland;United Kingdom;
AFQ056   
   Novartis Pharma Services AG
      2009   -   EUCTR2009-011743-39-GB   Germany;United Kingdom;
      2009   -   EUCTR2009-011743-39-DE   Germany;United Kingdom;United States;
   Novartis Pharmaceuticals
      2009   Phase 2   NCT01019473   Germany;United Kingdom;
AMT-130   
   uniQure biopharma B.V.
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-PL   Poland;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-DE   Germany;Poland;
ANX005   
   Annexon, Inc.
      2020   Phase 2   NCT04514367   United States;
Alprazolam   
   Pfizer
      2009   Phase 1   NCT00975481   Canada;
Amantadine   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001930   United States;
Anti-Parkinson medication   
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Atomoxetine   
   University of Iowa
      2005   Phase 2   NCT00368849   United States;
Autologous Stem Cell   
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01834053   India;
BEVANTOLOL HYDROCHLORIDE   
   SOM Biotech
      2018   Phase 2   EUCTR2018-000203-16-ES   Spain;
BID of PF-02545920   
   Pfizer
      2015   Phase 2   NCT02342548   Canada;Germany;Poland;United Kingdom;United States;
BN82451B   
   Ipsen
      2014   Phase 2   NCT02231580   Germany;
   Ipsen Pharma
      2014   Phase 2   EUCTR2013-002899-41-DE   Germany;
BN8251B   
   Ipsen Pharma
      2014   Phase 2   EUCTR2013-002899-41-DE   Germany;
Benerva   
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain;
BioStamp nPoint device   
   University of Rochester
      2020   Phase 2   NCT04201834   United States;
Biotina   
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain;
Blood sample   
   University Hospital, Angers
      2017   -   NCT03296176   France;
Branaplam   
   Novartis Pharmaceuticals
      2021   Phase 2   NCT05111249   Canada;France;Germany;Hungary;Spain;
Bupropion   
   Charite University, Berlin, Germany
      2012   Phase 2   NCT01914965   Germany;
CKD-504   
   Chong Kun Dang Pharmaceutical
      2018   Phase 1   NCT03713892   Korea, Republic of;
Calvan®   
   SOM Biotech
      2018   Phase 2   EUCTR2018-000203-16-ES   Spain;
Cellavita HD Higher dose   
   Azidus Brasil
      2017   Phase 1   NCT02728115   Brazil;
Cellavita HD Lower Dose   
   Azidus Brasil
      2017   Phase 1   NCT02728115   Brazil;
Cellavita HD higher dose   
   Azidus Brasil
      2018   Phase 2   NCT03252535   Brazil;
Cellavita HD lower dose   
   Azidus Brasil
      2018   Phase 2   NCT03252535   Brazil;
Cellavita-HD   
   Azidus Brasil
      2020   Phase 2/Phase 3   NCT04219241   Brazil;
CoQ10   
   Johns Hopkins University
      2010   Phase 2   NCT00920699   United States;
Coenzyme Q10   
   Massachusetts General Hospital
      2008   Phase 3   NCT00608881   Australia;Canada;United States;
Creatine   
   National Center for Complementary and Integrative Health (NCCIH)
      2001   Phase 1/Phase 2   NCT00026988   United States;
Creatine Monohydrate   
   Massachusetts General Hospital
      2009   Phase 3   NCT00712426   Australia;Canada;New Zealand;United States;
      2009   Phase 2   NCT01411150   United States;
Creatine monohydrate   
   Massachusetts General Hospital
      2010   Phase 2   NCT01411163   United States;
      2007   Phase 2   NCT00592995   United States;
      2005   Phase 2   NCT01412151   United States;
Cysteamine Bitartrate   
   Centre Hospitalier Universitaire d'Angers
      2010   -   EUCTR2010-019444-39-FR   France;
Deep Brain Stimulation   
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)   
   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
      2011   Phase 2   NCT01502046   Spain;
Deutetrabenazine   
   Vanderbilt University Medical Center
      2021   Phase 2/Phase 3   NCT04713982   United States;
Deutetrabenazine Oral Tablet [Austedo]   
   Fundacion Huntington Puerto Rico
      2020   Phase 1   NCT04301726   -
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China;
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)   
   The University of Texas Health Science Center, Houston
      2019   Phase 3   NCT03854019   United States;
Digoxin   
   Pfizer
      2009   Phase 1   NCT00831506   United States;
Dimebon   
   Medivation, Inc.
      2009   Phase 3   NCT00920946   Australia;Canada;Denmark;Germany;Sweden;United Kingdom;United States;
      2007   Phase 2   NCT00497159   United States;
      2006   Phase 1/Phase 2   NCT00387270   United States;
   Pfizer
      2009   Phase 1   NCT00975481   Canada;
      2009   Phase 1   NCT00831506   United States;
      2009   Phase 1   NCT00827034   United States;
      2009   Phase 1   NCT00825084   United States;
      2009   Phase 1   NCT00824590   United States;
Dimebon (latrepirdine)   
   Medivation, Inc.
      2010   Phase 3   NCT01085266   -
Dimebon + Dextromethorphan   
   Pfizer
      2008   Phase 1   NCT00788047   United States;
Dimebon + Ketoconazole   
   Pfizer
      2009   Phase 1   NCT00931073   United States;
Dimebon + Omeprazole   
   Pfizer
      2009   Phase 1   NCT00931073   United States;
Dimebon Dihydrochloride   
   Medivation, Inc.
      2007   Phase 2   EUCTR2007-003293-25-GB   United Kingdom;
Dimebon IR   
   Pfizer
      2009   Phase 1   NCT00990613   United States;
Dimebon IR Tablet   
   Pfizer
      2009   Phase 1   NCT00988624   United States;
Dimebon MR1   
   Pfizer
      2009   Phase 1   NCT00988624   United States;
Dimebon MR2   
   Pfizer
      2009   Phase 1   NCT00988624   United States;
Dimebon MR3   
   Pfizer
      2009   Phase 1   NCT00988624   United States;
Dimebon MR4   
   Pfizer
      2009   Phase 1   NCT00988624   United States;
Dimebon Transdermal   
   Pfizer
      2009   Phase 1   NCT00990613   United States;
Dimebon alone   
   Pfizer
      2009   Phase 1   NCT00931073   United States;
Dimebon dihydrochloride   
   MEDIVATION, INC.
      2010   -   EUCTR2009-018123-32-IT   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2009   -   EUCTR2009-011800-44-IT   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
   Medivation, Inc
      2010   -   EUCTR2009-018123-32-SE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2009-018123-32-NL   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2009-018123-32-GB   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2009-018123-32-DK   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2009-018123-32-DE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2009-011800-44-NL   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2009   -   EUCTR2009-011800-44-SE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2009   -   EUCTR2009-011800-44-GB   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2009   -   EUCTR2009-011800-44-DK   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2009   -   EUCTR2009-011800-44-DE   Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
Divalproex   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00095355   United States;
Ethyl Icosapent   
   Amarin Neuroscience Ltd
      2006   -   EUCTR2005-002088-98-PT   Germany;Italy;Portugal;Spain;United Kingdom;
Ethyl-EPA   
   Amarin Neuroscience Ltd
      2006   -   EUCTR2005-002088-98-PT   Germany;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002088-98-GB   Germany;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002088-98-ES   Germany;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002088-98-AT   Austria;Germany;Italy;Portugal;Spain;United Kingdom;
      -   -   EUCTR2005-002088-98-DE   Germany;Italy;Portugal;Spain;United Kingdom;
Ethyl-EPA (Miraxion™)   
   Amarin Neuroscience Ltd
      2005   Phase 3   NCT00146211   Canada;United States;
Ethyl-Icosapent   
   Amarin Neuroscience Ltd
      2005   -   EUCTR2005-002088-98-AT   Austria;Germany;Italy;Portugal;Spain;United Kingdom;
      -   -   EUCTR2005-002088-98-DE   Germany;Italy;Portugal;Spain;United Kingdom;
Fenofibrate   
   University of California, Irvine
      2017   Phase 2   NCT03515213   United States;
GSK356278   
   GlaxoSmithKline
      2011   Phase 1   NCT01602900   United Kingdom;
      2011   Phase 1   NCT01573819   Netherlands;
Graft intracerebral of foetal neurons   
   Assistance Publique - Hôpitaux de Paris
      2002   Phase 2   NCT00190450   France;
Haloperidol 2Mg Tab   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China;
High doses of Thiamine y Biotin   
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2022   Phase 2   NCT04478734   Spain;
ISIS 443139   
   Ionis Pharmaceuticals, Inc.
      2015   Phase 1/Phase 2   NCT02519036   Canada;Germany;United Kingdom;
Idebenone   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China;
LAX-101   
   Amarin Neuroscience Ltd
      2006   -   EUCTR2005-002088-98-PT   Germany;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002088-98-GB   Germany;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002088-98-ES   Germany;Italy;Portugal;Spain;United Kingdom;
      2005   -   EUCTR2005-002088-98-AT   Austria;Germany;Italy;Portugal;Spain;United Kingdom;
      -   -   EUCTR2005-002088-98-DE   Germany;Italy;Portugal;Spain;United Kingdom;
LMI070   
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-000105-92-IT   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2021   Phase 2   EUCTR2020-000105-92-ES   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-000105-92-LT   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-000105-92-HU   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-000105-92-FR   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-000105-92-DE   Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
LPM3770164 sustained release tablet simulant   
   Luye Pharma Group Ltd.
      2022   Phase 1   NCT05238701   China;
Laquinimod   
   Teva Branded Pharmaceutical Products R&D, Inc.
      2014   Phase 2   NCT02215616   Canada;Czech Republic;Czechia;France;Germany;India;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
Laquinimod capsules   
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   EUCTR2014-000418-75-NL   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-GB   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-DE   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-CZ   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-PT   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-IT   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Lithium   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00095355   United States;
Melatonin   
   The University of Texas Health Science Center, Houston
      2021   -   NCT04421339   United States;
Memantine   
   Jody Corey-Bloom, MD, PhD
      2004   Phase 4   NCT00652457   United States;
   University of British Columbia
      2011   Phase 2   NCT01458470   Canada;
Metformin   
   Instituto de Investigacion Sanitaria La Fe
      2021   Phase 3   NCT04826692   -
Minocycline   
   FDA Office of Orphan Products Development
      2001   Phase 1/Phase 2   NCT00029874   United States;
   Merit Cudkowicz
      2006   Phase 2/Phase 3   NCT00277355   Canada;United States;
Moderate doses of Thiamine y Biotin   
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2022   Phase 2   NCT04478734   Spain;
Neflamapimod   
   EIP Pharma Inc
      2019   Phase 2   NCT03980938   United Kingdom;
   EIP Pharma, Inc.
      2019   Phase 2   EUCTR2018-004840-51-GB   United Kingdom;
Nilotinib   
   Georgetown University
      2018   Phase 1   NCT03764215   United States;
OMS643762   
   Omeros Corporation
      2014   Phase 2   NCT02074410   United States;
OSU6162 similar to (-)-OSU 6162   
   A. Carlsson Research AB
      2014   Phase 2   EUCTR2013-002545-10-SE   Sweden;
Olanzapine   
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT00632645   France;
PBF-999   
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2014   Phase 1   NCT02208934   Spain;
PBF-999 /   
   Palobiofarma SL
      2016   Phase 1   NCT02907294   Spain;
PBT2   
   Prana Biotechnology Limited
      2012   Phase 2   NCT01590888   Australia;United States;
PF-02545920   
   Pfizer
      2014   Phase 2   NCT02197130   Canada;Germany;Poland;United Kingdom;United States;
      2013   Phase 2   NCT01806896   France;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2015   Phase 2   EUCTR2014-004900-31-DE   Canada;Germany;Poland;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001291-56-DE   Canada;Germany;Poland;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2015   Phase 2   EUCTR2014-001291-56-GB   Canada;Germany;Poland;United Kingdom;United States;
PL101   
   Prilenia Neurotherapeutics Ltd
      2020   Phase 3   EUCTR2020-002822-10-IT   Austria;Canada;Czech Republic;European Union;Germany;Italy;Netherlands;United Kingdom;United States;
   Prilenia Neurotherapeutics Ltd.
      2021   Phase 3   EUCTR2020-002822-10-NL   Austria;Czech Republic;Germany;Netherlands;
      2021   Phase 3   EUCTR2020-002822-10-CZ   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002822-10-AT   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002822-10-DE   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
PRIDOPIDINE HYDROCHLORIDE   
   Prilenia Neurotherapeutics Ltd
      2020   Phase 3   EUCTR2020-002822-10-IT   Austria;Canada;Czech Republic;European Union;Germany;Italy;Netherlands;United Kingdom;United States;
   Prilenia Neurotherapeutics Ltd.
      2021   Phase 3   EUCTR2020-002822-10-NL   Austria;Czech Republic;Germany;Netherlands;
      2021   Phase 3   EUCTR2020-002822-10-CZ   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002822-10-AT   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002822-10-DE   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
Phosphorus   
   Institut National de la Santé Et de la Recherche Médicale, France
      2012   -   NCT01696708   France;
Pridiopidine   
   Prilenia Neurotherapeutics Ltd.
      2021   Phase 3   EUCTR2020-002822-10-NL   Austria;Czech Republic;Germany;Netherlands;
      2021   Phase 3   EUCTR2020-002822-10-CZ   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002822-10-AT   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002822-10-DE   Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
Pridopidina   
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 2   EUCTR2015-000904-24-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Pridopidine   
   Prilenia
      2020   Phase 3   NCT04556656   Austria;Canada;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 2   NCT02494778   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   NCT02006472   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2011   Phase 2   NCT01306929   Canada;United States;
   Teva Branded Pharmaceutical Products R&D, Inc
      2016   Phase 2   EUCTR2015-000904-24-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-GB   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-001888-23-DK   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-PL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-NL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-IT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-AT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   -   EUCTR2013-001888-23-GB   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Pridopidine (90 mg)   
   Prilenia
      2017   Phase 1   NCT03019289   Germany;
RAAV5-miHTT   
   uniQure biopharma B.V.
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-PL   Poland;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-001461-36-DE   Germany;Poland;
RG6042, formerly ISIS 443139, IONIS-HTTRx   
   F. HOFFMANN - LA ROCHE LTD.
      2019   Phase 3   EUCTR2018-002987-14-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-PL   Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-NL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-GB   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-DK   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002471-25-DE   Canada;Germany;United Kingdom;
      2018   Phase 1;Phase 2   EUCTR2017-002471-25-GB   Canada;Germany;United Kingdom;
   Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
      2019   Phase 3   EUCTR2018-003898-94-ES   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
RO7234292   
   Hoffmann-La Roche
      2019   Phase 3   NCT03761849   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
RO7234292 (RG6042)   
   Hoffmann-La Roche
      2019   Phase 3   NCT03842969   Argentina;Australia;Austria;Canada;Chile;Germany;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
      2019   Phase 1   NCT04000594   Netherlands;United Kingdom;
      2018   Phase 2   NCT03342053   Canada;Germany;United Kingdom;
RP 103   
   Centre Hospitalier Universitaire d'Angers
      2010   -   EUCTR2010-019444-39-FR   France;
RP103   
   University Hospital, Angers
      2010   Phase 2/Phase 3   NCT02101957   France;
Ramelteon   
   Massachusetts General Hospital
      2009   -   NCT00907595   United States;
Resveratrol   
   Assistance Publique - Hôpitaux de Paris
      2015   -   NCT02336633   France;
Rilmenidine   
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2010   Phase 2   EUCTR2009-018119-14-GB   United Kingdom;
Riluzole   
   Sanofi
      1999   Phase 3   NCT00277602   -
Risperidone   
   University of Rochester
      2020   Phase 2   NCT04201834   United States;
Risperidone 1Mg Tab   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China;
Ro 723-4292/F02   
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2018-003898-94-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-PL   Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-NL   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-GB   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-DK   Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002987-14-AT   Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002471-25-DE   Canada;Germany;United Kingdom;
      2018   Phase 1;Phase 2   EUCTR2017-002471-25-GB   Canada;Germany;United Kingdom;
   Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
      2019   Phase 3   EUCTR2018-003898-94-ES   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Rolipram   
   GlaxoSmithKline
      2011   Phase 1   NCT01602900   United Kingdom;
SAGE-718   
   Sage Therapeutics
      2021   Phase 2   NCT05107128   -
      2019   Phase 1   NCT03787758   United States;
SBT-020   
   Stealth Bio Therapeutics Inc
      2017   Phase 2   EUCTR2016-003730-25-NL   Netherlands;
SD-809   
   Auspex Pharmaceuticals, Inc.
      2013   Phase 3   NCT01897896   Australia;Canada;United States;
   Teva Pharmaceutical Industries
      2013   Phase 3   NCT01795859   Australia;Canada;United States;
SEN0014196   
   SIENA BIOTECH SPA
      2011   -   EUCTR2011-001131-23-IT   Germany;Italy;United Kingdom;
   Siena Biotech S.p.A.
      2011   Phase 2   NCT01521585   Germany;
      2011   Phase 1   NCT01485965   United States;
      2009   Phase 1   NCT01521832   United Kingdom;
   Siena Biotech SpA
      2011   -   EUCTR2011-001131-23-GB   Germany;Italy;United Kingdom;
      2011   -   EUCTR2011-001131-23-DE   Germany;Italy;United Kingdom;
SEN0014196 (High Dose)   
   Siena Biotech S.p.A.
      2011   Phase 1   NCT01485952   Germany;
SEN0014196 (Low Dose)   
   Siena Biotech S.p.A.
      2011   Phase 1   NCT01485952   Germany;
SOM3355 100mg BID   
   SOM Biotech SL
      2018   Phase 2   NCT03575676   Spain;
SOM3355 200mg BID   
   SOM Biotech SL
      2018   Phase 2   NCT03575676   Spain;
SRX246   
   Azevan Pharmaceuticals
      2016   Phase 2   NCT02507284   United States;
SS-20   
   Stealth Bio Therapeutics Inc
      2017   Phase 2   EUCTR2016-003730-25-NL   Netherlands;
Selisistat   
   SIENA BIOTECH SPA
      2011   -   EUCTR2011-001131-23-IT   Germany;Italy;United Kingdom;
   Siena Biotech SpA
      2011   -   EUCTR2011-001131-23-GB   Germany;Italy;United Kingdom;
      2011   -   EUCTR2011-001131-23-DE   Germany;Italy;United Kingdom;
Sodium phenylbutyrate   
   University of Rochester
      2005   Phase 2   NCT00212316   United States;
TV-5600   
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   EUCTR2014-000418-75-NL   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-GB   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-DE   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-000418-75-CZ   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-PT   Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-IT   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000418-75-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
TV-7820   
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 2   EUCTR2015-000904-24-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
   Teva Branded Pharmaceutical Products R&D, Inc
      2016   Phase 2   EUCTR2015-000904-24-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-GB   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-DE   Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-000904-24-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-001888-23-DK   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-PL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-NL   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-IT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-001888-23-AT   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2014   -   EUCTR2013-001888-23-GB   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Tetrabenazine   
   Prestwick Pharmaceuticals
      2000   Phase 3   NCT00219804   -
   William Ondo, MD
      2018   Phase 4   NCT02509793   United States;
Tetrabenazine withdrawal   
   New York Medical College
      2013   Phase 4   NCT01834911   United States;
Tiapridal   
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT00632645   France;
Tominersen   
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2018-003898-94-IT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
   F.Hoffmann La-Roche Ltd
      2020   Phase 3   EUCTR2018-003898-94-NL   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003898-94-AT   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003898-94-GB   Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Triheptanoin   
   INSERM
      2015   Phase 2   EUCTR2014-005112-42-NL   France;Netherlands;
      2015   Phase 2   EUCTR2014-005112-42-FR   France;Netherlands;
Triheptanoin 1g/kg/day   
   Institut National de la Santé Et de la Recherche Médicale, France
      2013   Phase 2   NCT01882062   France;
Triheptanoin oil   
   Institut National de la Santé Et de la Recherche Médicale, France
      2015   Phase 2   NCT02453061   France;Netherlands;
UX007   
   INSERM
      2015   Phase 2   EUCTR2014-005112-42-NL   France;Netherlands;
      2015   Phase 2   EUCTR2014-005112-42-FR   France;Netherlands;
Ubiquinol   
   University of Rochester
      2009   Phase 1   NCT00980694   United States;
Ursodiol   
   Oregon Health and Science University
      2007   Phase 1   NCT00514774   United States;
VX-745   
   EIP Pharma, Inc.
      2019   Phase 2   EUCTR2018-004840-51-GB   United Kingdom;
VX15/2503   
   Vaccinex Inc.
      2015   Phase 2   NCT02481674   Canada;United States;
Valbenazine   
   Neurocrine Biosciences
      2020   Phase 3   NCT04400331   Canada;United States;
      2019   Phase 3   NCT04102579   Canada;United States;
Vitamin B7   
   Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
      2021   Phase 2   EUCTR2019-004360-22-ES   Spain;
WVE-003   
   Wave Life Sciences Ltd.
      2021   Phase 1/Phase 2   NCT05032196   Australia;Canada;Denmark;France;Germany;Poland;Spain;United Kingdom;
   Wave Life Sciences UK Limited
      2022   Phase 1;Phase 2   EUCTR2020-004556-15-NL   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-PL   Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-IT   Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-FR   Australia;Canada;Denmark;France;Germany;Poland;Spain;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-ES   Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2020-004556-15-DE   Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;
WVE-120101   
   Wave Life Science Ltd.
      2019   Phase 1;Phase 2   EUCTR2016-005095-10-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
   Wave Life Sciences Ltd.
      2020   Phase 1/Phase 2   NCT04617847   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2017   Phase 1/Phase 2   NCT03225833   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
   Wave Life Sciences UK Limited
      2020   Phase 2   EUCTR2019-003637-42-PL   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2020   Phase 2   EUCTR2019-003637-42-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2020   Phase 2   EUCTR2019-003637-42-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2020   Phase 2   EUCTR2019-003637-42-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2019   Phase 1;Phase 2   EUCTR2016-005095-10-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2019   Phase 1;Phase 2   EUCTR2016-005095-10-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2018   Phase 1;Phase 2   EUCTR2016-005095-10-GB   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
WVE-120102   
   WAVE Life Sciences Ltd
      2019   Phase 1;Phase 2   EUCTR2016-005142-39-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
   Wave Life Sciences Ltd.
      2019   Phase 1/Phase 2   NCT04617860   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2017   Phase 1/Phase 2   NCT03225846   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
   Wave Life Sciences UK Limited
      2020   Phase 2   EUCTR2019-002178-30-FR   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2020   Phase 2   EUCTR2019-002178-30-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2020   Phase 2   EUCTR2019-002178-30-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2019   Phase 2   EUCTR2019-002178-30-PL   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
      2019   Phase 1;Phase 2   EUCTR2016-005142-39-DK   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2016-005142-39-GB   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
      -   Phase 1;Phase 2   EUCTR2016-005142-39-DE   Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Warfarin   
   Pfizer
      2009   Phase 1   NCT00827034   United States;
Xenazine   
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT00632645   France;
Zoloft 50Mg Tablet   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 1   NCT04071639   China;
[123I]MNI-420   
   Institute for Neurodegenerative Disorders
      2009   Phase 1   NCT00970229   United States;
[18F]FPEB   
   Institute for Neurodegenerative Disorders
      2009   Phase 1   NCT00870974   United States;
daily citalopram   
   University of Iowa
      2005   Phase 2   NCT00271596   United States;